Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 3/20 | 0.35 |
| ▸ | PPARA | Q07869 | 2/20 | 0.35 |
| ▸ | TPMT | P51580 | 1/20 | 0.34 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | RXRB | P28702 | 1/20 | 0.33 |
| ▸ | RXRG | P48443 | 1/20 | 0.33 |
| ▸ | RARB | P10826 | 1/20 | 0.33 |
| ▸ | RARG | P13631 | 1/20 | 0.33 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29448808 | 1.00 | HCAR1 (0.46) | HCAR1SLC6A3HCAR2CES2CES1 | |
| SCHEMBL3638866 | 0.88 | RXRA (0.42) | HCAR1TPMTRXRARXRBRXRG | |
| SCHEMBL30056963 | 0.83 | CES2 (0.48) | CES2RXRARXRBRXRGMRGPRX4 | |
| SCHEMBL21609834 | 0.83 | CES2 (0.48) | CES2RXRARXRBRXRGMRGPRX4 | |
| SCHEMBL4388169 | 0.83 | RXRB (0.50) | TPMTRXRARXRBRXRGRARB | |
| SCHEMBL4969295 | 0.83 | NOTUM (0.44) | SLC6A3KDRL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL5007948 | 0.81 | TPMT (0.53) | HCAR1HCAR2TPMTRXRARXRB | |
| SCHEMBL5005131 | 0.81 | CA12 (0.50) | HCAR1TPMTRXRARXRBRXRG | |
| SCHEMBL17896562 | 0.80 | HCAR1 (0.53) | HCAR1SLC6A3HCAR2CES2CES1 | |
| SCHEMBL12398885 | 0.80 | NOTUM (0.41) | HCAR2TPMTRXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3412670-B1 | PYRIDINE DERIVATIVES INHIBITING RAF KINASE AND VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR, PHARMACEUTICAL COMPOSITION CONTAINING THEM AND USE THEREOF | SAMJIN PHARM CO LTD (KR) | 2022-03-09 | — | — | EP | disclosed |
| CN-109071543-B | Pyridine derivatives inhibiting RAF kinase and vascular endothelial growth factor receptor, process for their preparation, pharmaceutical compositions containing them and their use | 三进制药株式会社 | 2021-07-16 | — | — | CN | disclosed |
| US-10844062-B2 | Pyridine derivative inhibiting RAF kinase and vascular endothelial growth factor receptor, method for preparing same, pharmaceutical composition containing same, and use thereof | INCHEON UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION (KR) | 2020-11-24 | — | — | US | disclosed |
| US-20190300531-A1 | Pyridine Derivative Inhibiting RAF Kinase and Vascular Endothelial Growth Factor Receptor, Method for Preparing Same, Pharmaceutical Composition Containing Same, and Use Thereof | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2019-10-03 | — | — | US | disclosed |
| EP-3412670-A1 | PYRIDINE DERIVATIVE INHIBITING RAF KINASE AND VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR, METHOD FOR PREPARING SAME, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | Samjin Pharmaceutical Co., Ltd. (KR) | 2018-12-12 | — | — | EP | disclosed |
| US-20090118261-A1 | QUINAZOLINONE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
| EP-1831198-B1 | PYRIDINE CARBOXAMIDE DERIVATIVES FOR USE AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| US-20080306096-A1 | Quinazoline Derivatives, Process for Their Preparation and Their Use as Anti-Cancer Agents | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| EP-1966159-A2 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2008-09-10 | — | — | EP | disclosed |
| US-20080146570-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | US | disclosed |
| EP-1924573-A1 | B-RAF INHIBITORS | AstraZeneca AB (SE) | 2008-05-28 | — | — | EP | disclosed |
| WO-2007071963-A2 | QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTI-CANCER AGENTS | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | disclosed |
| EP-1789399-A1 | QUINAZOLINONE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | AstraZeneca AB (SE) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006079791-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2006-08-03 | — | — | WO | disclosed |
| WO-2006067445-A2 | CSF-1R KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006024834-A1 | QUINAZOLINONE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118261-A1 | QUINAZOLINONE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | BRAF, RAF1, ARAF | HCAR1 3674/4885SLC6A3 3464/4885HCAR2 3931/4885 |
| US-20080306096-A1 | Quinazoline Derivatives, Process for Their Preparation and Their Use as Anti-Cancer Agents | BRAF, RAF1, NRAS | HCAR1 4211/4885SLC6A3 2979/4885HCAR2 4206/4885 |
| US-20190300531-A1 | Pyridine Derivative Inhibiting RAF Kinase and Vascular Endothelial Growth Factor Receptor, Method for Preparing Same, Pharmaceutical Composition Containing Same, and Use Thereof | BRAF, KDR, RAF1 | HCAR1 1703/4885SLC6A3 3767/4885HCAR2 2008/4885 |
| US-20080146570-A1 | Chemical Compounds | BRAF, RAF1, NRAS | HCAR1 3347/4885SLC6A3 3909/4885HCAR2 3263/4885 |
| US-10844062-B2 | Pyridine derivative inhibiting RAF kinase and vascular endothelial growth factor receptor, method for preparing same, pharmaceutical composition containing same, and use thereof | BRAF, KDR, RAF1 | HCAR1 1703/4885SLC6A3 3767/4885HCAR2 2008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.